huA5BA2A Frozen Validation Report
343 PRS models · 1,636 protein predictions · 147 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Arterial and clotting tendency
near-term focus
The strongest near-term theme is cardiovascular: arterial disease, heart strain, clotting, vein inflammation, and vessel-wall traits cluster together, with some lipid-related protective nuance.
Full explanation
Several inherited signals sit at the far end for coronary artery disease, non-hypertensive heart failure, clotting, deep-vein thrombosis, vein inflammation, carotid artery thickness, and abdominal aortic aneurysm. This does not mean these conditions are present, but it does make cardiovascular prevention the clearest priority area in the report.
The pattern is not one-sided. A triglyceride-related score points in a protective direction, and the protein and variant evidence suggests this is more about vessel-wall biology, clotting tendency, and artery remodeling than a simple cholesterol-only story.
The practical implication is to treat routine cardiovascular basics as high value: blood pressure, cholesterol, glucose, smoking status, sleep, aerobic fitness, and waist trend matter because they can amplify or reduce inherited tendency.
This category becomes worth discussing sooner if there is chest discomfort, unusual breathlessness, one-sided leg swelling, sudden neurologic symptoms, known high blood pressure or cholesterol, abnormal clotting history, or strong family history of early heart disease, aneurysm, stroke, or blood clots.
What to watch forPrioritize routine cardiovascular prevention and bring this genetics context into care sooner if chest symptoms, unusual breathlessness, one-sided leg swelling, sudden neurologic symptoms, or strong family history are present.
Show technical evidence
Risk-score evidence
- congestive heart failure nonhypertensive: risk percentile 99.9%, coverage 100%, PGS001842.
- coronary atherosclerosis: risk percentile 99.1%, coverage 100%, PGS001839.
- blood clot or deep vein thrombosis: risk percentile 99%, coverage 85%, PGS000931.
- deep vein thrombosis: risk percentile 90.5%, coverage 89%, PGS001266.
- mean carotid imtat 120 150 210 240 degrees: risk percentile 87.4%, coverage 100%, PGS001966.
- triglycerides: risk percentile 4.4%, coverage 99%, PGS000847.
Protein pathway context
- MMP3: predicted level percentile 1.6%, R2 0.5052; pathway context only.
- PZP: predicted level percentile 91%, R2 0.5407; pathway context only.
- LRPAP1: predicted level percentile 2.1%, R2 0.6658; pathway context only.
Candidate variants
- CDKN2B-AS1 rs10757274 GG: context_variant.
- CDKN2A,CDKN2B rs10757278 GG: snpedia_context.
- CDKN2B-AS1 rs10757269 GG: snpedia_context.
- Variant rs10402271 TT: snpedia_context.
- LOC105377979 rs1015451 TT: snpedia_context.
Body composition and glucose handling
near-term focus
Body-size and visceral-fat signals are high, but several glucose and insulin signals are protective, making this a divergent metabolic pattern rather than a simple high-risk result.
Full explanation
The evidence points strongly toward larger body size, higher visceral-fat tendency, higher waist and weight-related traits, and a tendency toward recent weight change. Those signals matter because visceral fat and waist trend can influence blood pressure, lipids, sleep, liver enzymes, and long-term metabolic health.
At the same time, several glucose and insulin-related signals point in a protective direction. That means the inherited pattern is not simply saying poor glucose handling is inevitable. It suggests body composition may be the more important lever than assuming diabetes risk from genetics alone.
The protein and variant evidence adds metabolic pathway context, including digestion, body-size biology, adiposity distribution, and lipid handling. These are background signals, not blood tests.
This category becomes most useful to review if waist size rises, weight changes unexpectedly, energy or exercise tolerance shifts, routine glucose or cholesterol results change, blood pressure increases, or there is a family history of diabetes or early cardiovascular disease.
What to watch forUse waist trend, fitness, blood pressure, and routine glucose or lipid results as the practical triggers for action; favor steady body-composition habits over crash dieting.
Show technical evidence
Risk-score evidence
- predicted visceral adipose tissue: risk percentile 97.7%, coverage 97%, PGS000844.
- weight change compared with 1 year ago: risk percentile 97.5%, coverage 91%, PGS001006.
- weight: risk percentile 95.2%, coverage 96%, PGS003898.
- basal metabolic rate: risk percentile 2.4000000000000057%, coverage 96%, PGS003903.
- fasting proinsulin: risk percentile 93.1%, coverage 95%, PGS000840.
- non insulin dependent diabetes: risk percentile 86.7%, coverage 90%, PGS001294.
Protein pathway context
- LRPAP1: predicted level percentile 2.1%, R2 0.6658; pathway context only.
- PNLIPRP2: predicted level percentile 89%, R2 0.7241; pathway context only.
- TREH: predicted level percentile 88.5%, R2 0.5404; pathway context only.
- CGA: predicted level percentile 87.3%, R2 0.5201; pathway context only.
- XPNPEP2: predicted level percentile 10%, R2 0.5305; pathway context only.
Candidate variants
- RMST rs11109072 CC: snpedia_context.
- Variant rs10182181 GG: snpedia_context.
- Variant rs10089517 CC: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
- Variant rs10937273 GG: snpedia_context.
Kidney, urine mineral, and stone context
useful to review
The kidney-related pattern is mixed, but the strongest practical signal is urine-stone and mineral handling, with additional kidney-marker context.
Full explanation
The clearest signal in this category is a high inherited tendency around urinary stones and calcium handling. Other kidney-related scores involve creatinine, urine albumin, potassium in urine, and kidney filtration context.
This is not evidence of kidney disease. It is a tendency profile that says hydration, salt load, blood pressure, and routine kidney or urine results may be more informative than genetics alone.
The evidence is mixed rather than purely risk-skewed. Some kidney and gout-related signals point in a protective direction, while a kidney-linked protein and a kidney-marker variant add background context.
This category becomes worth reviewing if there is kidney-stone pain, blood in urine, recurring urinary symptoms, high calcium results, abnormal kidney or urine labs, high blood pressure, or a family history of stones or kidney disease.
What to watch forKeep hydration consistent and review this context if stone-like pain, blood in urine, recurring urinary symptoms, abnormal kidney or urine labs, or high calcium results appear.
Show technical evidence
Risk-score evidence
- urinary calculus: risk percentile 96.8%, coverage 100%, PGS001864.
- calcium: risk percentile 95.3%, coverage 100%, PGS001893.
- creatinine: risk percentile 94.5%, coverage 100%, PGS001945.
- microalbumin in urine: risk percentile 89.7%, coverage 100%, PGS001967.
- potassium in urine: risk percentile 87.5%, coverage 100%, PGS001974.
- estimated glomerular filtration rate: risk percentile 4.4%, coverage 100%, PGS000884.
Protein pathway context
- LILRB5: predicted level percentile 0%, R2 0.7926; pathway context only.
- LRPAP1: predicted level percentile 2.1%, R2 0.6658; pathway context only.
Candidate variants
- LOC107986166 rs10937329 TT: snpedia_context.
Immune and inflammatory balance
useful to review
Immune evidence is broad and mixed: shingles, sarcoidosis, Crohn's disease, and ulcerative colitis signals are elevated, while some autoimmune signals are protective.
Full explanation
The immune pattern is one of the more information-rich parts of the report. It includes high inherited signals for shingles, sarcoidosis, Crohn's disease, ulcerative colitis, Epstein-Barr virus antibody context, and several immune-cell signaling proteins.
The pattern is mixed. Protective-direction signals appear for rheumatoid arthritis, lupus, celiac disease, white blood cell count, and neutrophil percentage. This makes the category more about immune balance and response style than a single predicted disease.
Variant evidence adds joint and immune-disease context, while the protein evidence points to interferon, toll-like receptor, interleukin, antibody-receptor, and immune-activation pathways. These are pathway clues, not measured immune labs.
This category becomes worth discussing if there are shingles-like rashes, persistent unexplained inflammation, recurring fevers, chronic digestive inflammation, swollen joints, unexplained skin or eye inflammation, or a strong family history of autoimmune or inflammatory disease.
What to watch forKeep normal vaccination and prevention conversations current, and review this context if shingles-like rash, persistent inflammatory symptoms, recurring gut inflammation, or strong autoimmune family history is present.
Show technical evidence
Risk-score evidence
- zoster herpes zoster: risk percentile 95.6%, coverage 84%, PGS001131.
- sarcoidosis: risk percentile 94.3%, coverage 100%, PGS001872.
- crohn s disease: risk percentile 91.8%, coverage 83%, PGS001331.
- ulcerative colitis: risk percentile 86.8%, coverage 100%, PGS001855.
- rheumatoid arthritis: risk percentile 19.5%, coverage 100%, PGS004010.
- systemic lupus erythematosus: risk percentile 19.8%, coverage 99%, PGS000771.
Protein pathway context
- IFNGR2: predicted level percentile 1.7%, R2 0.6902; pathway context only.
- TLR3: predicted level percentile 2.9%, R2 0.8019; pathway context only.
- IL1RL1: predicted level percentile 2.5%, R2 0.5009; pathway context only.
- IL1RAP: predicted level percentile 96%, R2 0.706; pathway context only.
- CD300LF: predicted level percentile 96.5%, R2 0.5333; pathway context only.
- IL7R: predicted level percentile 86.9%, R2 0.5305; pathway context only.
Candidate variants
- Variant rs10865331 GG: snpedia_context.
- Variant rs10892279 GG: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
- LOC105376219 rs10980800 TT: snpedia_context.
Brain, mood, and cognitive-aging context
useful to review
Mood and cognitive-aging signals are mixed: depression-related scores are elevated, several anxiety and neuroticism traits are protective, and brain-region scores are research background only.
Full explanation
The brain-related evidence has two different layers. The first is mood and behavior: several depression-related scores are elevated, while some anxiety, neuroticism, low-mood, worry, and tiredness scores point in a protective direction.
The second layer is cognitive-aging and brain-region research context. Alzheimer-related scores are elevated, and several brain-region or brain-imaging scores sit at tail values. Those research-context rows are not diagnostic and should not be read as evidence of a brain condition by themselves.
The protein evidence adds nervous-system cell-signaling context. Overall, this category is best treated as background for resilience, sleep, stress load, mood, and cognitive health rather than as a prediction of a specific outcome.
This category becomes worth discussing if persistent mood change, loss of interest, sleep disruption, memory concerns, new neurologic symptoms, major life stress, medication changes, or strong family history of dementia or severe mood disorder are present.
What to watch forTreat sleep, stress load, mood persistence, memory concerns, and family history as the practical triggers for review; do not read the brain-region research signals as a diagnosis.
Show technical evidence
Risk-score evidence
- lifetime major depressive disorder: risk percentile 86.9%, coverage 98%, PGS000139.
- neuroticism score: risk percentile 4.2%, coverage 100%, PGS001996.
- feelings of worry or anxiety: risk percentile 6.9%, coverage 92%, PGS001021.
- alzheimers disease: risk percentile 94.5%, coverage 100%, PGS002035.
- total volume of white matter hyperintensities: risk percentile 99.1%, coverage 88%, PGS001534.
- volume of caudate: risk percentile 98.1%, coverage 89%, PGS001543.
Protein pathway context
- PSPN: predicted level percentile 89.9%, R2 0.5175; pathway context only.
- MDGA1: predicted level percentile 84.5%, R2 0.7077; pathway context only.
Gut, liver, and digestive pattern
useful to review
Digestive evidence includes bowel-frequency, reflux or ulcer, liver-enzyme, inflammatory bowel, and diverticular signals, with protective context for celiac and bilirubin-related traits.
Full explanation
The digestive pattern spans several areas rather than one condition. It includes high signals for bowel frequency, hiatus hernia, duodenal ulcer, gamma-glutamyl transferase, alanine aminotransferase, Crohn's disease, ulcerative colitis, and diverticular disease.
There are also protective-direction signals for celiac disease, bilirubin, and alkaline phosphatase. That makes the overall category mixed: digestion, inflammation, and liver-enzyme handling appear relevant, but the evidence does not point to one single digestive diagnosis.
Protein evidence adds digestive enzyme and metabolic pathway context. Variant evidence adds bilirubin and alkaline phosphatase context. These are genetic tendencies and should be interpreted against actual symptoms, alcohol intake, medications, and lab results.
This category becomes worth discussing if bowel habits change persistently, there is blood in stool, unexplained abdominal pain, reflux symptoms, unintentional weight change, abnormal liver enzymes, heavy alcohol exposure, or a family history of inflammatory bowel disease.
What to watch forUse persistent bowel changes, reflux or ulcer symptoms, abnormal liver-enzyme results, alcohol exposure, and family history as triggers to review this category.
Show technical evidence
Risk-score evidence
- average number of times bowels opened per day: risk percentile 94.7%, coverage 85%, PGS001376.
- hiatus hernia: risk percentile 92.2%, coverage 89%, PGS000939.
- duodenal ulcer: risk percentile 80.1%, coverage 79%, PGS001390.
- gamma glutamyl transferase: risk percentile 91.6%, coverage 97%, PGS000817.
- alanine aminotransferase: risk percentile 86.9%, coverage 100%, PGS001940.
- crohn s disease: risk percentile 91.8%, coverage 83%, PGS001331.
Protein pathway context
- PNLIPRP2: predicted level percentile 89%, R2 0.7241; pathway context only.
- TREH: predicted level percentile 88.5%, R2 0.5404; pathway context only.
- XPNPEP2: predicted level percentile 10%, R2 0.5305; pathway context only.
Candidate variants
- UGT1A6,UGT1A7,UGT1A8,UGT1A9,UGT1A10 rs1105879 AA: snpedia_context.
- Variant rs10892279 GG: snpedia_context.
Joints, tendons, and connective tissue
useful to review
Joint and connective-tissue evidence is risk-skewed, especially around Dupuytren-type fascia traits, arthritis, knee arthrosis, and tissue-remodeling proteins.
Full explanation
The musculoskeletal evidence clusters around palmar fascia contracture, general arthropathy, arthritis, knee arthrosis, and bone or heel ultrasound traits. This suggests connective tissue, joint loading, cartilage, and tissue remodeling are meaningful themes.
There is some protective nuance for falls and intervertebral disc traits, so this is not a blanket injury prediction. The strongest interpretation is that joint load management and mobility may be especially valuable over time.
Protein evidence points to cartilage and tissue-remodeling biology, and variant context overlaps with inflammatory joint biology. None of this proves joint disease is present.
This category becomes worth reviewing if there is hand thickening or finger contracture, persistent knee pain, swollen joints, reduced range of motion, recurring tendon pain, inflammatory back pain, or a training load that repeatedly irritates the same joints.
What to watch forBuild strength and mobility progressively, and review this context if hand contracture signs, persistent joint pain, swelling, reduced range of motion, or repeated training-related joint irritation appears.
Show technical evidence
Risk-score evidence
- contracture of palmar fascia dupuytren s disease: risk percentile 97.3%, coverage 100%, PGS001880.
- other arthropathies: risk percentile 95.2%, coverage 100%, PGS001877.
- arthritis: risk percentile 93.4%, coverage 88%, PGS001135.
- gonarthrosis arthrosis of knee: risk percentile 92.9%, coverage 90%, PGS001192.
- other intervertebral disk disorders: risk percentile 7.5%, coverage 88%, PGS000932.
- falls in the last year: risk percentile 15.6%, coverage 100%, PGS001916.
Protein pathway context
- CRTAC1: predicted level percentile 4%, R2 0.5057; pathway context only.
- MMP3: predicted level percentile 1.6%, R2 0.5052; pathway context only.
Candidate variants
- Variant rs10865331 GG: snpedia_context.
- Variant rs10892279 GG: snpedia_context.
Skin, hair, and sun response
background
Skin evidence is mixed: non-melanoma skin cancer, sunburn, sebaceous cyst, seborrheic keratosis, and hair-follicle signals are elevated, while melanoma scores are protective.
Full explanation
The skin-related evidence includes high inherited signals for non-melanoma skin cancer, childhood sunburn, sebaceous cysts, seborrheic keratosis, and hair or hair-follicle traits. Protein evidence adds skin-barrier and inflammatory signaling context.
The melanoma-related scores point in a protective direction, so this is not a uniform skin-cancer pattern. The most practical interpretation is that sun response and routine skin awareness matter, while the genetics is not saying a serious skin condition is present.
Variant context adds melanoma-related background, but it is weaker than a personal or family history and should not replace skin examination when something changes.
This category becomes worth reviewing if a spot changes, a lesion does not heal, there are recurrent cysts or inflamed follicles, unusual sun sensitivity, a strong family history of skin cancer, or frequent high-sun exposure.
What to watch forUse consistent sun protection and review changing spots, non-healing lesions, recurrent cysts, inflamed follicles, or strong skin-cancer family history promptly.
Show technical evidence
Risk-score evidence
- non melanoma skin cancer: risk percentile 96%, coverage 89%, PGS001040.
- childhood sunburn: risk percentile 90.8%, coverage 87%, PGS001257.
- sebaceous cyst: risk percentile 95.9%, coverage 100%, PGS001874.
- seborrheic keratosis: risk percentile 93.8%, coverage 89%, PGS001140.
- diseases of hair and hair follicles: risk percentile 89.2%, coverage 100%, PGS001873.
- melanoma: risk percentile 7.8%, coverage 97%, PGS003430.
Protein pathway context
- CCL24: predicted level percentile 12.8%, R2 0.7115; pathway context only.
- KLK12: predicted level percentile 12%, R2 0.7889; pathway context only.
Candidate variants
- ZHX2 rs10108684 GG: snpedia_context.
Eye and retinal context
background
Eye-related evidence points toward myopia, macular degeneration, retinal disorder, and diabetic-eye background signals.
Full explanation
The eye-related evidence includes inherited signals for myopia, macular degeneration, retinal disorders, and diabetic eye disease. A vision-related variant adds context for myopia, and another variant adds retinal background.
This does not mean any eye disease is present. It does suggest the eyes are a worthwhile place to connect genetics with real-world findings, especially because some eye conditions are silent early.
The diabetic-eye signal should not be read as evidence of diabetes. It is best interpreted alongside the metabolic section, where glucose handling is mixed and partly protective.
This category becomes worth reviewing if vision changes, night vision changes, distorted central vision, new floaters, eye pain, diabetes-related lab changes, high blood pressure, or family history of retinal disease are present.
What to watch forKeep routine eye care in mind and review this context if vision changes, distorted central vision, new floaters, eye pain, diabetes-related lab changes, or retinal family history appears.
Show technical evidence
Risk-score evidence
- myopia diagnosis: risk percentile 87%, coverage 100%, PGS001994.
- macular degenerationof retina nos: risk percentile 85.7%, coverage 100%, PGS001834.
- retinal disorders in diseases classified elsewhere: risk percentile 84.2%, coverage 80%, PGS001276.
- diabetic eye disease: risk percentile 93.3%, coverage 80%, PGS001028.
- 3mm weak meridian: risk percentile 5.7%, coverage 93%, PGS001362.
Candidate variants
- Variant rs10089517 CC: snpedia_context.
- CFI rs10033900 TT: snpedia_context.
Blood cell and iron context
background
Blood-related evidence includes high hematocrit, hemoglobin, red-cell, platelet-volume, and iron-status context, with some protective platelet and red-cell distribution signals.
Full explanation
The blood-trait evidence points toward higher hematocrit, hemoglobin, mean red-cell hemoglobin, and platelet volume. Protein and variant evidence add context around hemoglobin, folate-linked immune-cell biology, pregnancy-zone protein, iron status, and red-cell hemoglobin concentration.
There is protective nuance from platelet count, red-cell distribution width, and immature reticulocyte fraction. So the pattern is not simply high or low blood count; it is a blood-cell and iron-handling context.
This section matters partly because it can intersect with the clotting and cardiovascular section. Real blood count results, hydration status, altitude exposure, endurance training, smoking, and medications would heavily shape interpretation.
This category becomes worth discussing if routine blood counts are high or low, there is unexplained fatigue, breathlessness, unusual bruising, clotting history, iron abnormalities, high-altitude exposure, heavy endurance training, or a clinician flags blood-count changes.
What to watch forInterpret this through real blood-count and iron results, especially if fatigue, breathlessness, unusual bruising, clotting history, altitude exposure, endurance training, or abnormal labs are present.
Show technical evidence
Risk-score evidence
- haematocrit percentage: risk percentile 97.9%, coverage 100%, PGS001925.
- haemoglobin concentration: risk percentile 94.7%, coverage 92%, PGS001400.
- mean corpuscular hemoglobin: risk percentile 92.4%, coverage 100%, PGS001989.
- mean plateletvolume: risk percentile 89.4%, coverage 96%, PGS003934.
- platelet count: risk percentile 8.9%, coverage 96%, PGS003932.
- red blood celldistribution width: risk percentile 1.8%, coverage 100%, PGS001908.
Protein pathway context
- HBZ: predicted level percentile 92.1%, R2 0.5431; pathway context only.
- FOLR3: predicted level percentile 9.8%, R2 0.9226; pathway context only.
- PZP: predicted level percentile 91%, R2 0.5407; pathway context only.
Candidate variants
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
- GPT,LOC101928953 rs1063739 CC: snpedia_context.
Hormone and male reproductive context
background
High testosterone-related signals, male reproductive cancer scores, prostate-related proteins, male fertility protein context, and prostate variant evidence create a male-health awareness category.
Full explanation
The male reproductive and hormone evidence includes high testosterone-related scores, an insulin-like growth factor score, male genital tract cancer and testicular cancer scores, prostate-related protein predictions, and prostate-cancer variant context.
This is not a diagnosis and does not mean hormone levels are high on a blood test. Genetically predicted protein levels and inherited scores are background tendencies, while actual interpretation depends on age, symptoms, family history, exam findings, and lab results.
The prostate-related protein evidence includes predicted PSA and prostate secretory protein context. That can affect how real prostate screening results are interpreted, but it does not replace clinician-guided screening.
This category becomes worth discussing if there are urinary changes, testicular lumps or pain, fertility concerns, unexpected libido or energy changes, abnormal hormone or prostate labs, or a family history of prostate, testicular, or male reproductive cancers.
What to watch forUse age, family history, urinary changes, testicular symptoms, fertility concerns, and real hormone or prostate results as the triggers for review.
Show technical evidence
Risk-score evidence
- testosterone: risk percentile 97.1%, coverage 100%, PGS001914.
- testosterone nmol l: risk percentile 95.7%, coverage 93%, PGS000696.
- igf 1: risk percentile 82.6%, coverage 100%, PGS001960.
- testicular cancer: risk percentile 88.8%, coverage 71%, PGS001164.
- male genital tract cancer: risk percentile 84.5%, coverage 69%, PGS001111.
Protein pathway context
- KLK3: predicted level percentile 10.8%, R2 0.6695; pathway context only.
- MSMB: predicted level percentile 12%, R2 0.5861; pathway context only.
- TEX101: predicted level percentile 14.3%, R2 0.5681; pathway context only.
- CGA: predicted level percentile 87.3%, R2 0.5201; pathway context only.
Candidate variants
- Intergenic rs10896449 GG: snpedia_context.
- Variant rs10505483 CC: snpedia_context.
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
Lung and airway context
background
Respiratory evidence is divergent: one airway-ratio signal and lung-cancer score are elevated, while other lung-function and chronic-airway signals are protective.
Full explanation
The lung-related evidence is not one-directional. One airway-ratio score sits in a risk direction, and a lung-cancer score is elevated. At the same time, lung-function and chronic-airway obstruction signals point in protective directions.
This means the category is best treated as respiratory awareness rather than a prediction of lung disease. Environment, smoking status, occupational exposure, air pollution, infection history, and actual breathing symptoms would dominate interpretation.
Immune and airway-related protein predictions add inflammatory pathway context, which overlaps with the immune and skin sections.
This category becomes worth discussing if there is persistent cough, wheeze, unexplained breathlessness, reduced exercise tolerance, chest symptoms, smoking history, occupational exposure, or strong family history of lung disease or lung cancer.
What to watch forUse breathing symptoms, exercise tolerance, smoking or occupational exposure, and family history as the practical triggers for reviewing this respiratory context.
Show technical evidence
Risk-score evidence
- lung function: risk percentile 7.200000000000003%, coverage 93%, PGS001237.
- forced expiratory volume in 1 second best measure: risk percentile 11.700000000000003%, coverage 100%, PGS001918.
- chronic airway obstruction: risk percentile 4.8%, coverage 100%, PGS001850.
- lung cancer: risk percentile 88.7%, coverage 87%, PGS001392.
Protein pathway context
- IL1RL1: predicted level percentile 2.5%, R2 0.5009; pathway context only.
- IL1RAP: predicted level percentile 96%, R2 0.706; pathway context only.
- CCL24: predicted level percentile 12.8%, R2 0.7115; pathway context only.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.